Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibr...

Source: BMC Pulmonary Medicine - April 27, 2018 Category: Respiratory Medicine Authors: M. Molina-Molina, C. Machahua-Huamani, V. Vicens-Zygmunt, R. Llatj ós, I. Escobar, E. Sala-Llinas, P. Luburich-Hernaiz, J. Dorca and A. Montes-Worboys Tags: Research article Source Type: research